Treatment News : Incivek Improves Outcome and Halves Treatment Time for Hep C in HIV-Positive Men

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 20, 2013

Incivek Improves Outcome and Halves Treatment Time for Hep C in HIV-Positive Men

CROI 2013Adding Incivek (telaprevir) to the standard regimen of pegylated interferon and ribavirin doubles the cure rate and cuts in half the treatment time for acute hepatitis C virus (HCV) among HIV-positive men, reports. Daniel Fierer, MD, from Mount Sinai Medical Center in New York City conducted an open-label pilot study to determine how the addition of Incivek to the older backbone of interferon and ribavirin affected treatment outcomes among this group.  He presented his findings at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta.
Between July 2011 and September 2012, Fierer treated HIV-positive men who had presented elevated liver enzyme tests—indicating a recent hep C infection—and who then tested positive for hepatitis C. Within six months of their first elevated liver scan (which people with HIV typically undergo routinely to test for antiretroviral medication toxicity) the study participants began a 12-week combination of telaprevir three times a day, pegylated interferon 2a injected once a week and ribavirin twice a day.

A total of 17 out of 20 participants (85 percent) achieved a sustained virologic response four weeks after completing treatment (SVR4, considered a likely cure). In another group of patients for whom there is longer follow-up data, 14 out of 17 (82 percent) achieved an SVR12 (considered a very likely cure) after completing therapy; also, 11 out of 14 (79 percent) achieved an SVR24 (considered a cure).

Nearly every patient experienced itchiness, and two developed rashes. One participant terminated treatment after four weeks due to anemia requiring a blood transfusion, and an additional three reduced their doses of ribavirin due to the same adverse effect. Another participant dropped out of the study at five weeks because of interferon side effects.

To read the story, click here.

To read the conference abstract, click here.

Search: Incivek, telaprevir, pegylated interferon, ribavirin, Daniel Fierer, Mount Sinai Medical Center,, hepatitis C, hep C, virus, 20th Conference on Retroviruses and Opportunistic Infections, CROI, liver enzymes, sustained virologic response, SVR.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.